Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease - PubMed (original) (raw)

Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease

Diederik F van Wijk et al. Arterioscler Thromb Vasc Biol. 2010 Jul.

Abstract

Objective: In humans, evidence about the association between levels of monocyte chemoattractant protein-1 (MCP-1), its coding gene chemokine (C-C motif) ligand 2 (CCL2), and risk of coronary artery disease (CAD) is contradictory.

Methods and results: We performed a nested case-control study in the prospective EPIC-Norfolk cohort investigating the relationship between CCL2 single-nucleotide polymorphisms (SNPs), MCP-1 concentrations, and the risk of future CAD. Cases (n=1138) were apparently healthy men and women aged 45 to 79 years who developed fatal or nonfatal CAD during a mean follow-up of 6 years. Controls (n=2237) were matched by age, sex, and enrollment time. Using linear regression analysis no association between CCL2 SNPs and MCP-1 serum concentrations became apparent, nor did we find a significant association between MCP-1 serum levels and risk of future CAD. Finally, Cox regression analysis showed no significant association between CCL2 SNPs and the future CAD risk. In addition, we did not find any robust associations between the CCL2 haplotypes and MCP-1 serum concentration or future CAD risk.

Conclusions: Our data do not support previous publications indicating that MCP-1 is involved in the pathogenesis of CAD.

PubMed Disclaimer

Cited by

Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals.
Georgakis MK, Malik R, Björkbacka H, Pana TA, Demissie S, Ayers C, Elhadad MA, Fornage M, Beiser AS, Benjamin EJ, Boekholdt SM, Engström G, Herder C, Hoogeveen RC, Koenig W, Melander O, Orho-Melander M, Schiopu A, Söderholm M, Wareham N, Ballantyne CM, Peters A, Seshadri S, Myint PK, Nilsson J, de Lemos JA, Dichgans M. Georgakis MK, et al. Circ Res. 2019 Sep 27;125(8):773-782. doi: 10.1161/CIRCRESAHA.119.315380. Epub 2019 Sep 3. Circ Res. 2019. PMID: 31476962 Free PMC article.
The associations between the MCP-1 -2518 A/G polymorphism and ischemic heart disease and ischemic stroke: a meta-analysis of 28 research studies involving 21,524 individuals.
Cai G, Zhang B, Weng W, Shi G, Huang Z. Cai G, et al. Mol Biol Rep. 2015 May;42(5):997-1012. doi: 10.1007/s11033-014-3836-8. Epub 2014 Nov 21. Mol Biol Rep. 2015. PMID: 25413568
MCP-1 rs1024611 Polymorphism, MCP-1 Concentrations, and Premature Coronary Artery Disease: Results of the Genetics of Atherosclerotic Disease (GEA) Mexican Study.
Posadas-Sánchez R, Velázquez-Sánchez F, Reyes-Barrera J, Cardoso-Saldaña G, Velázquez-Argueta F, Antonio-Villa NE, Fragoso JM, Vargas-Alarcón G. Posadas-Sánchez R, et al. Biomedicines. 2024 Jun 11;12(6):1292. doi: 10.3390/biomedicines12061292. Biomedicines. 2024. PMID: 38927499 Free PMC article.
Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study.
Canouï-Poitrine F, Luc G, Mallat Z, Machez E, Bingham A, Ferrieres J, Ruidavets JB, Montaye M, Yarnell J, Haas B, Arveiler D, Morange P, Kee F, Evans A, Amouyel P, Ducimetiere P, Empana JP; PRIME Study Group. Canouï-Poitrine F, et al. Neurology. 2011 Sep 20;77(12):1165-73. doi: 10.1212/WNL.0b013e31822dc7c8. Epub 2011 Aug 17. Neurology. 2011. PMID: 21849651 Free PMC article. Clinical Trial.
Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias.
Apostolakis S, Amanatidou V, Spandidos DA. Apostolakis S, et al. Acta Pharmacol Sin. 2010 Sep;31(9):1103-10. doi: 10.1038/aps.2010.131. Epub 2010 Aug 16. Acta Pharmacol Sin. 2010. PMID: 20711227 Free PMC article. Review.

References

1. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, Van Damme J, Wadhwa M, Yoshie O, Zlotnik A, Zoon K. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res. 2002;22:1067–1068. - PubMed
1. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–621. - PubMed
1. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28:1897–1908. - PubMed
1. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–1127. - PMC - PubMed
1. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwartz CJ, Sonenshein GE. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci U S A. 1992;89:6953–6957. - PMC - PubMed

Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease - PubMed (original) (raw)